02/19/2025, 08:31 AM UTC
辉瑞股价上涨空间更大Pfizer Stock's Upside Got Bigger
1、辉瑞股价被评为‘买入’，预计上涨空间为45%，得益于强劲的每股收益增长和成本削减举措；2、2024财年第四季度业绩显示，非COVID销售额同比增长12%，调整后的每股收益超出预期37%；3、辉瑞强劲的研发管线预计将推动未来增长，并抵消专利到期的影响。1. Pfizer's stock is rated 'Buy' with a projected 45% upside due to strong EPS growth and cost reduction initiatives; 2. Q4 FY2024 results showed significant earnings beats, with non-COVID sales up 12% YoY and adjusted EPS beating consensus by 37%; 3. Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations.---
本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
